Companies › Umoja Biopharma
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| UB-VV111 CD19 CAR T cell therapy generated in vivo via gene therapy | CD19 | Phase 1 | Lymphoma, B-Cell | Mar 2029 |
| UB-VV400 CD22-directed CAR T cell therapy | CD22 | Phase 1 | Lymphoma, B Cell | Aug 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06528301 | UB-VV111 | Phase 1 | Lymphoma, B-Cell | Oncology | Mar 2029 |
| NCT07735533 | UB-VV400 | Phase 1 | Lymphoma, B Cell | Oncology | Aug 2031 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.